Following encouraging earlier-phase clinical data, the Company is advancing its acne trial ahead of schedule while maintaining atopic dermatitis global P...
Phase I results provide platform-level validation supporting AdJane's broader development programs in pandemic preparedness, respiratory infectious disea...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...
Corten Capital and Ampersand Capital Partners (“Ampersand”) are pleased to announce the completion of their acquisition of Beacon Intelligenc...
Further expansion of the existing strategic partnership reflects continued high demand for Lonza’s high-quality global biologics outsourcing de...
Helvoet is an advanced medical CDMO specializing in highly automated micro-molding and precision injection molding for microfluidics, diagnostics, an...
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturin...
Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing pl...
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults wit...
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise ...
Anivive converts Laverdia-CA1 to full FDA approval First FDA-approved product to validate Anivive's AI-enabled development model — from drug rep...
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physi...
Complaint filed in San Diego County Superior Court seeks specific performance, alleging NRx warranted it had funds to close while concealing it lacked ...
First and only CDK4/6 inhibitor approved for HR+ metastatic disease regardless of HER2 status Approval based on data from the collaborative Phase 3 ...
© 2026 Biopharma Boardroom. All Rights Reserved.
